Invest in

Biotech Breakthroughs

3.0%
11.4%
2.4%

Feeling Better About Biotech

The next big cure for a complex, scary disease is unlikely to come from old-school pharma. It’s likely coming from biotech. Scientists, investors, and patients are all banking on the $93 billion biotech industry.[1] It’s outpaced Big Pharma in finding treatments for cancer, AIDS, multiple sclerosis, and other diseases. The FDA approved 43 drugs in 2012, a 20% jump from the previous year.[4] Big Pharma has responded by snapping up promising biotech and smaller pharmaceutical companies, at lofty valuations, with premiums for several public companies in excess of 50%.[2] In fact, 2013 was a big year for the biotech industry, with $29B in M&A deals through the 1st half of 2013.[3] This motif includes only biotech companies with at least two years of cash flow to help screen out companies at greater risk of losing money. See More
3.0%
11.4%
2.4%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for as low as $9.95.
Join over 100,000 Motif customers customizing, building, and sharing motifs.
Portfolio Index 1 YR Return
Open a Motif account to view and trade this thematic portfolio
Weight Segment & Stocks Symbol 1 YR Return
51.3% Research & Diagnostics 4.5%
10.3% Danaher Corporation DHR 7.5%
10.0% 8xxxxx 8xxxxx 8xxxxxxxxx 8xxx 8xx 88.8%
4.8% 8xxxx 8xxxxxxx 8xxx 8xx 88.8%
4.7% 8xxxx 8xxxxxxxxxx 8xxxxxxxxxxx 8xx 88.8%
4.6% 8xxxxxx 8xxxxxxxxxxx 8xx 8 88.8%
4.5% 8xxxxxxxxx 8xxxxxxxxxx 8x 8xxxxxx 8xxxxx 8x 88.8%
3.6% 8xxxxx 8xxxxxxxxxx 8xx 88.8%
3.0% 8xxxxxx 8xxxxxxxxxxx 8xxx 8xx 8xx 88.8%
2.5% 8xxxxxxxxx 8xxx 8xxx 88.8%
1.3% 8xxxxxx 8xxxxxxxxxx 8xxx 88.8%
1.1% 8xxxxxxxxxxxxx 8xxxxxxxxxxxx 8xxx 8xx 88.8%
1.0% 8xxxxxxxxxx 8xxx 8xx 88.8%
26.9% Other Biotech 13.0%
10.4% Amgen Inc. AMGN 9.6%
6.0% 8xxxxx 8xxxxxxxxxxxxxx 8xxxxxxxxxxx 8xxx 88.8%
5.8% 8xxxxxxxx 8xxxxxxxxxxxxxx 8xxx 8xxx 88.8%
1.4% 8xxxxx 8x 8xxx 88.8%
1.2% 8xxxxxx 8xxx 8xxx 88.8%
1.0% 8xxxxx 8xxxxxxxxxxx 8x 8xxx 88.8%
0.9% 8xxxxxxx 8xxx 8xxx 88.8%
15.8% Mature Biotechnology 20.6%
10.8% Gilead Sciences Inc. GILD 16.6%
5.0% 8xxxxx 8xxx 8xxx 88.8%
2.3% Early Commercial Biotech 9.6%
2.3% 8xxxxxxx 8xxxxxxxxxxxxx 8xxx 8xxx 88.8%
2.0% Commercial Growth Biotech 37.6%
2.0% 8xxxxxx 8xxxxxxxxxxxxxx 8xxx 8xxx 88.8%
1.7% Development Stage Biotech 12.7%
0.9% 8xxxxxxx 8xxxxxxxxxxx 8xxx 8xxx 88.8%
0.7% 8xxxxx 8xxxxxxxxxxxxxx 8xxxxxxxxxxx 8xxx 88.8%
Quotes delayed 15 mins. Currently Mar 30, 2020 1:50:48 AM. Fields are marked with -- when data is unavailable.